Ventilator Acquired Pneumonia
Conditions
Keywords
cost effectiveness, linezolid, ventilator acquired pneumonia, central america
Brief summary
The therapy with Linezolid (LIN) represents better cost-effectiveness vs. Vancomycin (VAN) for the treatment of nosocomial Pneumonia associate to ventilator (VAP).
Interventions
DRUGLinezolid
Treatment for VAP as indication approved and as physician criterium.
Sponsors
Pfizer
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Evidence of a legally acceptable representative signed and dated informed consent document indicating that him or her has been informed of all pertinent aspects of the study. * Adult (18 years old or older) men and women with confirm diagnosis of VAP treated on ICU with LIN or VAN; on the selected institutions.
Exclusion criteria
* Adult men or women with nosocomial pneumonia not associated to a ventilator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The rate of resistance Empirical treatment days before specific therapy. Treatment days with Linezolid. Treatment days with Vancomycin. | 4 months |
| Rate of renal failure. | 4 months |
| Rate of healing with Linezolid. | 4 months |
| Rate of healing with Vancomycin. | 4 months |
Secondary
| Measure | Time frame |
|---|---|
| Variation of prices and values among the different institutions. | 4 months |
| The average costs of each intervention. | 4 months |
| Hospitalization days average with VAN and Linezolid. | 4 months |
Outcome results
None listed